Advanced Solid Tumor
748
261
334
158
Key Insights
Highlights
Success Rate
63% trial completion
Published Results
44 trials with published results (6%)
Research Maturity
158 completed trials (21% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
12.6%
94 terminated out of 748 trials
62.7%
-23.8% vs benchmark
0%
1 trials in Phase 3/4
28%
44 of 158 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 158 completed trials
Clinical Trials (748)
Study of SGN1 in Patients With Advanced Solid Tumor
Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors
Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor
Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors
A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of HBM1020 in Subjects With Advanced Solid Tumors
A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations
Study of LP-184 in Patients With Advanced Solid Tumors
Study in Advanced Solid Tumor Patients
Clinical Experience and Real-world Safety and Effectiveness of Envafolimab: Patient Access Program
Mirdametinib + BGB-3245 in Advanced Solid Tumors
A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours
Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations
Study of ZG005 in Patients With Advanced Solid Tumors
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
Safety of AM-928 Infusion in Advanced Solid Tumors